Trial Profile
Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATOC (Primary) ; Indium-111-pentetreotide
- Indications Medulloblastoma; Neuroblastoma; Neuroendocrine tumours; Phaeochromocytoma
- Focus Adverse reactions; Diagnostic use
- 13 Jan 2021 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2019.
- 09 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.